KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Common Equity (2016 - 2026)

Amgen has reported Common Equity over the past 18 years, most recently at $9.2 billion for Q1 2026.

  • For Q1 2026, Common Equity rose 48.06% year-over-year to $9.2 billion; the TTM value through Mar 2026 reached $9.2 billion, up 48.06%, while the annual FY2025 figure was $8.7 billion, 47.32% up from the prior year.
  • Common Equity for Q1 2026 was $9.2 billion at Amgen, up from $8.7 billion in the prior quarter.
  • Over five years, Common Equity peaked at $9.6 billion in Q3 2025 and troughed at $916.0 million in Q1 2022.
  • A 5-year average of $6.0 billion and a median of $6.2 billion in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 90.19% in 2022 and later soared 483.84% in 2023.
  • Year by year, Common Equity stood at $3.7 billion in 2022, then surged by 70.23% to $6.2 billion in 2023, then dropped by 5.7% to $5.9 billion in 2024, then surged by 47.32% to $8.7 billion in 2025, then rose by 6.14% to $9.2 billion in 2026.
  • Business Quant data shows Common Equity for AMGN at $9.2 billion in Q1 2026, $8.7 billion in Q4 2025, and $9.6 billion in Q3 2025.